Faricimab + Ranibizumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Choroidal Neovascularization Secondary to Pathologic Myopia
Conditions
Choroidal Neovascularization Secondary to Pathologic Myopia
Trial Timeline
Mar 6, 2024 → May 29, 2026
NCT ID
NCT06176352About Faricimab + Ranibizumab
Faricimab + Ranibizumab is a phase 3 stage product being developed by Roche for Choroidal Neovascularization Secondary to Pathologic Myopia. The current trial status is active. This product is registered under clinical trial identifier NCT06176352. Target conditions include Choroidal Neovascularization Secondary to Pathologic Myopia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06176352 | Phase 3 | Active |
| NCT02699450 | Phase 2 | Completed |
Competing Products
20 competing products in Choroidal Neovascularization Secondary to Pathologic Myopia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| ranibizumab | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Everolimus + Ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| ranibizumab 0.5mg | Novartis | Phase 2 | 52 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal injection ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 1/2 | 41 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Intravitreal Pegaptanib | Pfizer | Pre-clinical | 22 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Regeneron Pharmaceuticals | Pre-clinical | 22 |